Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene

1 Oct 2018

Abstract excerpt

Abstract: Severe, life-threatening adverse reactions to capecitabine sometimes occur in the treatment of solid tumors. Screening for dihydropyrimidine dehydrogenase (DPYD) deficiency is encouraged before start of treatment, but the genetic variants that are commonly analyzed often fail to explain toxicities seen in clinical practice. Here we describe the case of a 79-year-old Caucasian female with breast cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30349384
DOI: 10.2147/cmar.s174470

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) genePMID 30349384Read ↗

Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.Semantic proximity Read ↗

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.Semantic proximity Read ↗

New advances in DPYD genotype and risk of severe toxicity under capecitabine.Semantic proximity Read ↗

Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).Semantic proximity Read ↗

DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.Semantic proximity Read ↗

All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly GuideSemantic proximity Read ↗

Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

DPYD (Dihydropyrimidine Dehydrogenase) Variant c.2194G>A (Normal Metabolizer) with Severe Toxicities in Patients Treated with Fluoropyrimidine Based Regimens. A first Case Report from Bihar, IndiaSemantic proximity Read ↗

Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.Semantic proximity Read ↗

Opportunistic analysis of clinically actionable DPYD gene variants in a germline testing cohort in India.Semantic proximity Read ↗

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the LiteratureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.